RecruitingNCT06156384

Study to Assess the Pain, Satisfaction, and Quality of Life of Patients With FITBONE® Lengthening Nail

Prospective, Observational Study to Assess the Pain, Satisfaction, and Quality of Life of Patients Implanted With the FITBONE® Lengthening Nail


Sponsor

Orthofix s.r.l.

Enrollment

45 participants

Start Date

Jun 18, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

This study is a prospective observational non-interventional multi-centre cohort study of patients, 12 years or older, initiating a lower limb lengthening procedure with FITBONE and who have a length discrepancy of 30mm or more between the limbs. The following parameters will be assessed for up to 24 months. * Pain using the Visual Analog Scale (VAS), Patient Global Assessment (PGA) and Clinical Observer Global Assessment (COGA) * Patient satisfaction using the Patient Global Impression of change (PGI-C) scale * QoL using the 36-Item Short Form Survey/Paediatric Quality of Life Inventory (SF-36/PedsQL)


Eligibility

Min Age: 12 Years

Inclusion Criteria4

  • Patients aged ≥12 years old, with congenital or acquired lower limb discrepancy greater than 30mm, undergoing femoral or tibia bone lengthening with FITBONE
  • Patients with a regular indication for a surgical intervention with FITBONE according to manufacturer IFU
  • The patient (or his/her legally acceptable representative) is capable of understanding the content of the Informed Consent Form (ICF)
  • The informed consent form is correctly obtained

Exclusion Criteria5

  • Patients with a medical condition that is contraindicated according to the FITBONE instruction for use.
  • Patients with any conditions that, in the Investigator's opinion, may interfere with the study execution, including those likely to be lost to follow-up.
  • Patients who have any conditions or medical condition that, in the investigator's opinion, may interfere with the study's execution or in which the patient should not participate for safety reasons.
  • Patients requiring the application of or have already in-situ concomitant devices that cannot be safely removed (except for permitted concomitant devices).
  • Patients participating in other clinical or have taken part in any clinical study in the last 3 months.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEFITBONE® Lengthening Nail

The patient is installed on a standard orthopaedic table, intramedullary reaming is performed through a metal working tube. The osteotomy is performed percutaneously and then an osteotome according to the postage-stamp technique. Once the FITBONE lengthening nail is placed in the desired location, it should be connected to the subcutaneous receiver. The receiver should be placed close enough to the skin surface to ensure the energy transfer from the external transmitter. After 5 to 10 days after surgery, the lengthening mechanism is operated by the patient, using the transmitter. An elongation of approximately 1 mm/day takes place. The attending physician determines the rhythm of lengthening in each case. When the desired elongation length is reached, the consolidation phase begins, which is necessary for bone regeneration. The FITBONE lengthening nail can be removed once the bone has consolidated, approximately one to one and a half years after implantation.


Locations(6)

CHU de Saint-Étienne Hôpital Nord

Saint-Etienne, Auvergne-Rhône-Alpes, France

CHU de Strasbourg

Strasbourg, Grand Est, France

CHU Lille - Hôpital Jeanne de Flandre

Lille, Hauts-de-France, France

Centre hospitalier universitaire (CHU) de Toulouse

Toulouse, Occitanie, France

Hôpital Sainte-Marguerite AP-HM

Marseille, Provence-Alpes-Côte d'Azur Region, France

CHU de La Réunion site Sud Saint-Pierre

Saint-Pierre, La Réunion, Reunion

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06156384